# Synthesis and Antimicrobial Activity of 3-(1-Aryl-1*H*-1,2,3-triazol-4-yl)-2-(4-fluorophenyl)-1-(2-hydroxy-4-methoxyphenyl)propan-1-ones<sup>1</sup>

# M. Nagamani<sup>*a*</sup>, Ch. Anjaiah<sup>*b*</sup>, D. Praveen<sup>*a*</sup>, and P. Jalapathi<sup>*a*\*</sup>

<sup>a</sup> Department of Chemistry, University College of Science, Saifabad, Osmania University, Hyderabad, Telangana, 500004 India \*e-mail: pochampalli.ou.chemi@gmail.com

<sup>b</sup> Department of Chemistry, University College of Science, Osmania University, Hyderabad, Telangana, 500004 India

Received March 2, 2018

**Abstract**—A number of novel 3-(1-aryl-1*H*-1,2,3-triazol-4-yl)-2-(4-fluorophenyl)-1-(2-hydroxy-4-methoxy-phenyl)propan-1-ones has been synthesized from 2-(4-fluorophenyl)-1-(2-hydroxy-4-methoxyphenyl)ethanone by its propargylation followed by the click reaction. Structures of all the newly synthesized compounds were characterized by <sup>1</sup>H and <sup>13</sup>C NMR, and Mass spectra. Their antimicrobial activity was evaluated.

Keywords: fluorinated organic molecule, propargylation, click reaction, 1,2,3-triazole, antimicrobial activity

DOI: 10.1134/S107036321804028X

#### **INTRODUCTION**

Fluorinated compounds are highly lipophilic which allows their molecules to be easily delivered to the active sites across the living body. Since there is only a limited number of naturally occurring fluorinecontaining compounds, there is a certain demand in developing synthetic approaches to fluorinated organic compounds with biological potential. 1,2,3-Triazole and its derivatives demonstrate diverse biological activities such as antimicrobial [1], antiproliferative [2], antibacterial [3], anti-HIV [4], antifungal [5], anticancer [6], and antitubercular [7]. Based on the above, we have synthesized 3-(1-aryl-1*H*-1,2,3-triazol-4-yl)-2-(4-fluorophenyl)-1-(2-hydroxy-4-methoxyphenyl)propan-1-ones (Scheme 1).

#### **RESULTS AND DISCUSSION**

A number of novel 3-(1-aryl-1*H*-1,2,3-triazol-4-yl)-2-(4-fluorophenyl)-1-(2-hydroxy-4-methoxyphenyl)propan-1-ones (**3a–3h**) has been synthesized from 2-(4fluorophenyl)-1-(2-hydroxy-4-methoxyphenyl)ethanone (**1**) by its propargylation in the presence of K<sub>2</sub>CO<sub>3</sub> in dry acetone to afford 2-(4-fluorophenyl)-1-(2-hydroxy-4-methoxyphenyl)pent-4-yn-1-one (**2**). Upon treatment of the compound **2** by various aryl azides in the presence of CuSO<sub>4</sub>·5H<sub>2</sub>O and sodium ascorbate in *t*-BuOH–H<sub>2</sub>O media the title compounds were accumulated with high yields. Spectral analysis, <sup>1</sup>H and <sup>13</sup>C NMR, and mass spectra, supported the structures of all synthesised compounds.

Antimicrobial activity. All synthesized compounds were screened for antibacterial activity against five gram positive and five gram negative bacterial strains: *M. Tuberculosis, M. Luteus, MRSA, B. Subtilis, B. Cereus, P. Aerginosa, K. Pneumonia, E. Coli, P. Vulgaris,* and *S. Typhi* using Gentamycin as a standard drug [8–10]. Among all compounds **3b** and **3d** demonstrated the highest activity against *K. Pneumonia* and *E. Coli.* The compounds **3a** and **3d** were most active against *K. pneumonia* and *E. coli.* The compounds **3a** and **3f** demonstrated the pronounced activity against *B. Subtilis* and *B. Cereus.* 


Antifungal activity. The synthesized compounds were also screened for antifungal activity against five fungal strains, including *T. Interdigitale, E. Floccosum, M. Canis, M. Gypseums*, and *Rubrum* using Nystatin as a standard drug [8–10]. The compound **3b** inhibited completely *M. Canis* and *M. Gypseums* and demonstrated the moderate activity against *T. Interdigitale*.

# EXPERIMENTAL

Melting points were determined in open capillary tubes and are uncorrected. Purity of the compounds was tested by TLC using precoated silica gel plates 60<sub>254</sub> (Merck). <sup>1</sup>H and <sup>13</sup>C NMR spectra were measured on a Bruker Avance II 400 MHz spectrometer using

<sup>&</sup>lt;sup>1</sup> The text was submitted by the authors in English.

Scheme 1. Synthetic pathway to 3-(1-aryl-1H-1,2,3-triazol-4-yl)-2-(4-fluorophenyl)-1-(2-hydroxy-4-methoxyphenyl)propan-1-ones.



a: propargyl bromide, K<sub>2</sub>CO<sub>3</sub>, dry acetone; b: R-N<sub>3</sub>, CuSO<sub>4</sub>·5H<sub>2</sub>O, sodium ascorbate, t-butanol, water.

TMS as an internal standard. Mass spectra were measured on a GCMS-QP 1000 EX mass spectrometer. Elemental analysis was carried out on a Thermo Finnigan CHNS analyzer.

Synthesis of 2-(4-fluorophenyl)-1-(2-hydroxy-4methoxyphenyl)pent-4-yn-1-one (2). A mixture of 2-(4-fluorophenyl)-1-(2-hydroxy-4-methoxyphenyl)ethanone (1) (1 mmol) with propargyl bromide (1.2 mmol) and potassium corbonate in dry acetone was refluxed for 8 h under TLC control. Upon completion of the process, the was mixture cooled down to room temperature and poured in ice cold water The precipitated solid was filtered off, washed with water and purified by column chromatography using ethyl acetate: heaxane as an eluent. Yield 55%, mp 164–166°C. <sup>1</sup>H NMR spectrum, δ, ppm: 1.94–1.96 t (1H, CH), 2.64–2.71 d.d (1H, CH<sub>2</sub>), 2.94–3.01 d.d (1H, CH<sub>2</sub>), 3.80 s (3H, OCH<sub>3</sub>), 4.67–4.71 d.d (1H, CH), 6.35-6.40 m (2H, ArH), 6.99-7.03 m (2H, ArH), 7.28-7.31 m (2H, ArH), 7.61-7.63 d (1H, ArH), 12.68 s (1H, OH). <sup>13</sup>C NMR spectrum,  $\delta_{C}$ , ppm: 29.7, 55.5, 61.6, 77.2, 101.0, 107.6, 108.0, 115.9, 116.1, 128.8, 129.5, 130.5, 132.2, 167.69, 189.4. MS 299  $[M - H]^+$ .

Synthesis of 3-(1-Aryl-1*H*-1,2,3-triazol-4-yl)-2-(4fluorophenyl)-1-(2-hydroxy-4-methoxyphenyl)propan-1-ones (3a–3h). A mixture of 2-(4-fluorophenyl)-1-(2-hydroxy-4-methoxyphenyl)pent-4-yn-1one (2) (1 mmol) with a certain azide (1 mmol), CuSO<sub>4</sub>·5H<sub>2</sub>O and sodium ascorbate in *t*-BuOH–H<sub>2</sub>O (2 : 1) was stirred at room temperature until completion of the reaction according to TLC (15–20 h). Then it was poured into ice cold water. The precipitated solid was filtered off and purified by column chromatography using ethyl acetate: heaxane as an eluent.

**2-(4-Fluorophenyl)-1-(2-hydroxy-4-methoxyphenyl)-3-(1-phenyl-1***H***-1,2,3-triazol-4-yl)propan-1one (3a). Yield 84%, mp 180–182°C. <sup>1</sup>H NMR spectrum, \delta, ppm: 3.18–3.24 d.d (1H, CH<sub>2</sub>), 3.62–3.68 d.d (1H, CH<sub>2</sub>), 3.76 s (3H, OCH<sub>3</sub>), 5.11–5.15 d.d (1H,**  CH), 6.32–6.35 m (2H, ArH), 7.01–7.06 m (2H, ArH), 7.27–7.34 m (3H, ArH), 7.37–7.40 m (2H, ArH), 7.45– 7.54 m (2H, ArH), 7.58–7.73 m (2H, ArH), 12.76 s (1H, OH). <sup>13</sup>C NMR spectrum,  $\delta_C$ , ppm: 29.8, 51.6, 55.6, 66.6, 101.0, 107.8, 112.8, 115.9, 116.4, 120.2, 120.4, 128.6, 128.8, 129.5, 129.6, 129.7, 130.9, 132.0, 132.2, 134.8, 134.8, 136.9, 166.1, 166.2, 167.6, 202.7. MS 418 [M - H]<sup>+</sup>.

**3-[1-(2-Chlorophenyl)-1***H***-1,2,3-triazol-4-yl]-2-(4fluorophenyl)-1-(2-hydroxy-4-methoxyphenyl)propan-1-one (3b).** Yield 77%, mp 202–204°C. <sup>1</sup>H NMR spectrum,  $\delta$ , ppm: 3.24–3.29 d.d (1H, CH<sub>2</sub>), 3.62– 3.68 d.d (1H, CH<sub>2</sub>), 3.78 s (3H, OCH<sub>3</sub>), 5.08–5.12 d.d (1H, CH), 6.34–6.46 m (2H, ArH), 6.98–7.01 m (2H, ArH), 7.27–7.32 m (2H, ArH), 7.39–7.42 m (2H, ArH), 7.50–7.55 m (2H, ArH), 7.68–7.73 m (2H, ArH), 12.77 s (1H, OH). <sup>13</sup>C NMR spectrum,  $\delta_{\rm C}$ , ppm: 29.6, 51.6, 55.5, 61.6, 101.0, 107.8, 112.8, 115.8, 116.1, 127.6, 127.8, 128.8, 129.5, 129.6, 130.6, 130.9, 132.0, 132.2, 166.1, 166.2, 167.6, 202.7. MS 452  $[M - H]^+$ .

**3-[1-(3-Chlorophenyl)-1***H***-1,2,3-triazol-4-yl]-2-(4fluorophenyl)-1-(2-hydroxy-4-methoxyphenyl)propan-1-one (3c).** Yield 80%, mp 191–193°C. <sup>1</sup>H NMR spectrum,  $\delta$ , ppm: 3.17–3.22 d.d (1H, CH<sub>2</sub>), 3.61– 3.67 d.d (1H, CH<sub>2</sub>), 3.75 s (3H, OCH<sub>3</sub>), 5.12–5.19 d.d (1H, CH), 6.32–6.35 m (2H, ArH), 6.86–7.01 m (2H, ArH), 7.28–7.46 m (5H, ArH), 7.63–7.68 m (2H, ArH), 7.81–7.83 m (1H, ArH), 12.77 s (1H, OH). <sup>13</sup>C NMR spectrum,  $\delta_{\rm C}$ , ppm: 29.6, 51.6, 55.5, 61.6, 101.0, 107.8, 112.8, 115.8, 116.1, 127.6, 127.8, 128.8, 129.5, 129.6, 130.6, 130.9, 132.0, 132.2, 166.1, 166.2, 167.6, 202.7. MS 452 [*M* – H]<sup>+</sup>.

**2-(4-Fluorophenyl)-1-(2-hydroxy-4-methoxyphenyl)-3-[1-(***p***-tolyl)-1***H***-1,2,3-triazol-4-yl]propan-<b>1-one (3d).** Yield 86%, mp 175–177°C. <sup>1</sup>H NMR spectrum, δ, ppm: 1.85 s (1H, CH<sub>3</sub>), 3.10–3.16 d.d (1H, CH<sub>2</sub>), 3.45–3.51 d.d (1H, CH<sub>2</sub>), 3.72 s (3H, OCH<sub>3</sub>), 5.01–5.08 d.d (1H, CH), 6.33–6.35 m (2H, ArH), 6.82–6.88 m (2H, ArH), 7.13–7.20 m (2H, ArH), 7.28–7.32 m (2H, ArH), 7.49–7.56 m (2H, ArH), 7.60–7.65 m (2H, ArH), 12.58 s (1H, OH). <sup>13</sup>C NMR spectrum,  $\delta_{\rm C}$ , ppm: 25.5, 29.8, 55.8, 61.2, 100.4, 102.8, 120.4.1, 124.5, 127.2, 128.4, 129.5, 130.0, 131.6, 134.8, 155.1, 161.7, 166.3, 166.7, 167.0, 202.8. MS 433  $[M - H]^+$ .

**2-(4-Fluorophenyl)-1-(2-hydroxy-4-methoxyphenyl)-3-[1-(4-methoxyphenyl)-1***H***-1,2,3-triazol-4yl]propan-1-one (3e). Yield 79%, mp 183–185°C. <sup>1</sup>H NMR spectrum, \delta, ppm: 3.20–3.26 d.d (1H, CH<sub>2</sub>), 3.52– 3.58 d.d (1H, CH<sub>2</sub>), 3.77 s (3H, OCH<sub>3</sub>), 3.80 s (1H, OCH<sub>3</sub>), 5.08–5.15 d.d (1H, CH), 6.34–6.36 m (2H, ArH), 6.88–6.94 m (4H, ArH), 7.27–7.38 m (4H, ArH), 7.56–7.63 m (2H, ArH), 12.71 s (1H, OH). <sup>13</sup>C NMR spectrum, \delta\_{C}, ppm: 30.2, 52.1, 55.8, 56.3, 61.5, 99.3, 100.6, 112.4, 116.8, 118.9, 122.3, 126.5, 128.7, 129.5, 129.6, 130.4, 1314, 135.6, 155.5, 161.2, 166.7, 167.1, 167.5, 202.4. MS 447 [M – H]<sup>+</sup>.** 

**2-(4-Fluorophenyl)-1-(2-hydroxy-4-methoxyphenyl)-3-{1-[4-(trifluoromethoxy)phenyl]-1***H***-1,2,3triazol-4-y})propan-1-one (3f). Yield 75%, mp 212– 214°C. <sup>1</sup>H NMR spectrum, \delta, ppm: 3.19–3.23 d.d (1H, CH<sub>2</sub>), 3.58–3.64 d.d (1H, CH<sub>2</sub>), 3.765 s (3H, OCH<sub>3</sub>), 5.08–5.12 d.d (1H, CH), 6.34–6.37 m (2H, ArH), 6.99– 7.04 m (2H, ArH), 7.24–7.30 m (2H, ArH), 7.38–7.40 m (2H, ArH), 7.54–7.65 m (2H, ArH), 12.76 s (1H, OH). <sup>13</sup>C NMR spectrum, \delta\_{C}, ppm: 29.5, 51.5, 55.5, 66.4, 96.5, 100.8, 107.6, 111.2, 112.2, 120.2, 126.5, 127.6, 128.8, 129.5, 130.1, 130.7, 131.4, 133.2, 135.7, 160.4, 166.2, 167.6, 202.3. MS 502 [M – H]<sup>+</sup>.** 

**2-(4-Fluorophenyl)-1-(2-hydroxy-4-methoxyphenyl)-3-[1-(2,4,6-trimethoxyphenyl)-1***H***-1,2,3-triazol-4-yl]propan-1-one (3g). Yield 82%, mp 179– 181°C. <sup>1</sup>H NMR spectrum, \delta, ppm: 3.16–3.22 d.d (1H, CH<sub>2</sub>), 3.59–3.65 d.d (1H, CH<sub>2</sub>), 3.88 s (3H, OCH<sub>3</sub>), 3.92 s (9H, OCH<sub>3</sub>), 5.14–5.18 d.d (1H, CH), 6.33–6.35 m (2H, ArH), 6.84–6.88 m (2H, ArH), 6.95–7.01 m (2H, ArH), 7.30–7.33 m (2H, ArH), 7.55–7.83 m (2H, ArH), 12.76 s (1H, OH). <sup>13</sup>C NMR spectrum, \delta\_{\rm C}, ppm: 29.6, 52.1, 56.3, 61.5, 98.2, 101.0, 117.4, 119.1, 129.5, 129.6, 129.8, 128.7, 130.9, 132.2, 135.6, 155.5, 161.5, 166.0, 166.2, 167.5, 170.5, 202.5. MS 508 [M - H]^+.** 

**2-(4-Fluorophenyl)-1-(2-hydroxy-4-methoxyphenyl)-3-[1-(4-nitrophenyl)-1***H***-1,2,3-triazol-4-yl]propan-1-one (3h). Yield 85%, mp 196–198°C. <sup>1</sup>H NMR spectrum, \delta, ppm: 3.19–3.24 d.d (1H, CH<sub>2</sub>), 3.63– 3.69 d.d (1H, CH<sub>2</sub>), 3.77 s (3H, OCH<sub>3</sub>), 5.13–5.17 d.d (1H, CH), 6.33–6.40 m (2H, ArH), 6.98–7.03 m (2H, ArH), 7.28–7.36 m (2H, ArH), 7.62–7.73(m, 2H,**  ArH), 7.88–7.90 m (2H, ArH), 8.35-8.37 m (2H, ArH), 12.72 s (1H, OH). <sup>13</sup>C NMR spectrum,  $\delta_{\rm C}$ , ppm: 30.1, 51.4, 55.5, 61.6, 101.0, 107.9, 116.0, 116.2, 119.0, 120.1, 120.3, 123.9, 124.4, 125.4, 128.8, 129.4, 129.5, 130.9, 132.0, 132.2, 147.0, 166.1, 166.3, 167.6, 202.4. MS 463  $[M - H]^+$ .

## ACKNOWLEDGMENTS

The authors are thankful to the Head, Department of Chemistry for providing laboratory facilities. The authors are also thankful to the Director, Central Facilities for Research and Development (CFRD), Osmania University for providing IR and NMR spectral analysis and also thankful to University College of Science, Saifabad, Osmania University.

## REFERENCES

- Pervaram, S., Ashok, D., Rao, B.A., Sarasija, M., and Reddy, C.V.R., *Russ. J. Gen. Chem.*, 2017, vol. 87, p. 2454. doi 10.1134S1070363217100280
- Sowjanya, T., Jayaprakash Rao, Y., and Murthy, N.Y.S., *Russ. J. Gen. Chem.*, 2017, vol. 87, p. 1864. doi 10.1134/S1070363217080357
- Guo, Y., Liu, C., Song, H., Wang, F.L., Zou, Y., Wu, Q.Y., and Hu, H.G., *RSC Adv.*, 2017, vol. 7, p. 2110. doi 10.1039/C6RA26617G
- Silva, F.D.C.D., Souza, M.C.B.V.D., Frugulhetti, I.I.P., Castro, H.C., Souza, S.L.D.O., Souza, T.M.L.D., Rodrigues, D.Q., Souza, A.M.T., Abreu, P.A., Passamani, F., Rodrigues, C.R., and Ferreira, V.F., *Eur. J. Med. Chem.*, 2009, vol. 44, p. 373. doi 10.1016/ j.ejmech.2008.02.047
- Kouznetsov, V.V., Gomez, C.M.M., Derita, M.G., Svetaz, L., Olmo, E.D., and Zacchino, S.A., *Bioorg. Med. Chem.*, 2012, vol. 20, p. 6506. doi 10.1016/ j.bmc.2012.08.036
- Zhang, D.W., Zhang, Y.M., Li, J., Zhao, T.Q., Gu, Q., and Lin, F., *Ultrason. Sonochem.*, 2017, vol. 36, p. 343. doi 10.1016/j.ultsonch.2016.12.011
- Gill, C., Jadhav, G., Shaikh, M., Kale, R., Ghawalkar, A., Nagargoje, D., and Shiradkar, M., *Bioorg. Med. Chem. Lett.*, 2008, vol. 18, p. 6244. doi 10.1016/j.bmcl.2008.09.096
- Nagamani, M., Kishore Kumar, A., Sunitha, V., Jalapathi, P., Jayasree, D., and Shravan Kumar, G., *Der Pharma Chemica*, 2017, vol. 9(4), p. 36.
- Kishore Kumar, A., Sunitha, V., Shankar, B., Krishna, T.M., Lincoln, Ch.A., and Jalapathi, P., *Russ. J. Gen. Chem.*, 2017, vol. 87, p. 2011. doi 10.1134/S1070363217090171
- Sunitha, V., Kishore Kumar, A., Shankar, B., Anil Kumar, A., Krishna, T.M., Lincoln, Ch.A., and Jalapathi, P., *Russ. J. Gen. Chem.*, 2017, vol. 87, p. 322. doi 10.1134/S1070363217020281